Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 21, 2019

Study Completion Date

January 21, 2019

Conditions
Autoimmune Hepatitis
Interventions
DRUG

JKB-122

Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.

Trial Locations (16)

10029

Mount Sinai Hospital, New York

27710

Duke University Medical Center, Durham

46202

Indiana University School of Medicine, Indianapolis

60611

Northwestern University, Chicago

75203

Methodist Dallas Medical Center, Dallas

77030

Advanced Liver Therapies, Baylor College of Medicine, Houston

78215

The Texas Liver Institute, San Antonio

90036

Ruane Clinical Research Group, Inc., Los Angeles

95817

University of California Davis Medical Center - Ticon 1, Sacramento

98104

Swedish Medical Center - Organ Transplant and Liver Center, Seattle

University of Washington, Seattle

Unknown

California Pacific Medical Center, San Francisco

Tulane University, New Orleans

Massachusetts General Hospital, Boston

Taxes Liver Institute, San Antonio

32610-0272

University of Florida Hepatology Research at CTRB, Gainesville

All Listed Sponsors
lead

TaiwanJ Pharmaceuticals Co., Ltd

INDUSTRY

NCT02556372 - Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies | Biotech Hunter | Biotech Hunter